Dekas platform has the potential to enable discoveries of next generation therapies, said Richard Lubin.

JUPITER, Fla. (PRWEB) February 27, 2020

An upcoming episode of Advancements with Ted Danson, scheduled to broadcast 2Q/2020, will explore innovative treatment solutions for maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohns Disease (Crohns), and Oncology. Check local listings for more info.

This segment will focus on a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), that will enable the delivery of next generation cytokine or combination of cytokines to a specific tissue of interest. Viewers will learn how this cutting-edge technology, termed Diakines, has led to the development of two potential therapeutic molecules involving an affinity modified Interleukin 10 cytokine.

The show will also explore how Deka Biosciences is using Diakines to harness the spectrum of therapeutically useful and clinically validated IL10 and other cytokine specific biologies. Spectators will see how these Diakines can maximize patient benefits through improved PK/PD function combined with a MOA directed patient selection strategy.

The biopharma industry has known for a while that cytokines play an integral role in immunology and disease management, and that delivery of cytokine therapeutics into diseased tissues will dramatically enhance therapeutic benefit, said Dr. John Mumm, co-founder & CEO of Deka Biosciences. He continued to say, Deka Biosciences has harnessed the wealth of clinical knowledge around cytokines and IL-10 in particular, to develop a novel delivery platform to enrich cytokine variants in effected tissues, coupled with methods to determine how to select the patients with the greatest likelihood of response to ensure that the right patients get the right medicines.

In addition, the show will also inform about Deka Biosciences Precision Medicine strategy, which enables Deka to identify the right patients to treat with these new medicines.

Dekas platform has the potential to enable discoveries of next generation therapies, said Richard Lubin, senior producer for DMG Productions and the Advancements series. We are eager to explore how Deka is set to influence future treatment options for IBD, Crohns.

About Deka Biosciences:Deka BioSciences, Inc., is an early-stage biotech focused on creating the next generation targeted cytokine therapies to treat chronic illnesses such as Crohns Disease and Oncology. Dekas focus is on the development of optimized disease specific IL-10 variants coupled with the DiakinesTM T1/2 life extension tissue targeting technology. In parallel, Deka has developed a Precision Medicine strategy by identifying the genetic signature that drives responses to treatment to enable the selection of the patients most likely to benefit from our therapies.

About Advancements and DMG Productions:The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing todays consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.

For more information, please visit http://www.AdvancementsTV.com or call Richard Lubin at 866-496-4065.

Share article on social media or email:

See more here:
Next-generation Targeted Cytokine Therapy to be Explored on Advancements Series - PR Web

Comments are closed.